"QMG is a healthcare provider with strengths in primary and speciality care. An essential part of our community since 1937, we celebrated reaching 1000 employees in 2017. Through the years, we’ve maintained the close connection to our patients that sets us apart. Some of our doctors have treated three generations of the same families. Over the years, we’ve embraced change, and listened to our community. Today, with expanded hours and new ways to keep in touch, we’re easier than ever to work with. And even as we adapt and grow, we never lose sight of what makes a healthcare organization great: providing an unparalleled care experience for the tri-states."

During the past decade, Quincy Medical Group conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 24 clinical trials were completed, i.e. on average, 92.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 14 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Quincy Medical Group" #1 sponsor was "Bristol-Myers Squibb" with 6 trials, followed by "Alliance for Clinical Trials in Oncology" with 4 trials sponsored, "National Cancer Institute (NCI)" with 4 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Quincy Medical Group" #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Canadian Cancer Trials Group" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "American Cancer Society, Inc." with 1 trials as a collaborator and "American Society of Clinical Oncology" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Quincy Medical Group" are "Rheumatoid Arthritis" (3 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (3 trials), "Stage II Lung Non-Small Cell Cancer AJCC v7" (3 trials), "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Quincy Medical Group" in a lesser frequency.

Most popular intervention types in "Quincy Medical Group" are "Drug" (31 trials), "Other" (11 trials), "Biological" (7 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Carboplatin" (5 trials), "Clinical Observation" (3 trials), "Ipilimumab" (3 trials) and "Laboratory Biomarker Analysis" (3 trials). Other intervention names were less common.

The vast majority of trials in "Quincy Medical Group" are 38 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Quincy Medical Group". undefined are not yet recruiting, 4 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Quincy Medical Group, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Quincy Medical Group, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".